Get the Weekly Intelligence Brief — top committee picks every Sunday.

ENSG vs RARE

Ensign Group vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
ENSG
Ensign Group
69
Buy
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
MetricENSGRARE
AI Score 69 56
Price $180.10 $26.96
P/E Ratio 27.43× -4.62×
ROE 15.4% 718.8%
Revenue Growth YoY
Gross Margin 14.1% 83.1%
Debt / Equity 0.92× -4.13×
Dividend Yield 0.1% 0.0%
RSI (14) 71.8 54.3
Beta 0.694 0.313
Expected Upside +5.3%

AI Committee View

Current Innellis committee reasoning for ENSG versus RARE.
ENSG leads by 13 points.

ENSG scores 69/100 (Buy) versus RARE at 56/100 (Watch).

ENSG Committee View
50% agreement
4 analysts

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • RSI at 72 is in overbought territory — Technical
RARE Committee View
50% agreement
4 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Price structure making lower highs and lower lows — Technical
  • Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
  • Bollinger bandwidth of 27.5% signals elevated volatility — Risk
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ENSG Full Analysis RARE Full Analysis